HR 137 — A Resolution recognizing May 17, 2025, as "World Neurofibromatosis Awareness Day" in Pennsylvania.
Congress · introduced 2025-03-19
Latest action: — (Remarks see House Journal Page 660-661), May 13, 2025
Sponsors
- Steven R. Malagari (D, PA-53) — sponsor · 2025-03-19
- Carol Hill-Evans (D, PA-95) — cosponsor · 2025-03-19
- Robert Freeman (D, PA-136) — cosponsor · 2025-03-19
- Arvind Venkat (D, PA-30) — cosponsor · 2025-03-19
- Jose Giral (D, PA-180) — cosponsor · 2025-03-19
- Tarik Khan (D, PA-194) — cosponsor · 2025-03-19
- Jim Haddock (D, PA-118) — cosponsor · 2025-03-19
- Benjamin V. Sanchez (D, PA-153) — cosponsor · 2025-03-19
- Scott Conklin (D, PA-77) — cosponsor · 2025-03-19
- Dan K. Williams (D, PA-74) — cosponsor · 2025-03-19
- G. Roni Green (D, PA-190) — cosponsor · 2025-03-19
- Gina H. Curry (D, PA-164) — cosponsor · 2025-03-19
- Keith S. Harris (D, PA-195) — cosponsor · 2025-03-19
Action timeline
- · house — Referred to HEALTH, March 19, 2025
- · house — Reported as committed, April 9, 2025
- · house — Adopted, May 13, 2025 (201-2)
- · house — (Remarks see House Journal Page 660-661), May 13, 2025
Text versions
No text versions on file yet — same ingest as the action timeline populates these. Each version has direct links to the XML / HTML / PDF at govinfo.gov.
Bill text
Printer's No. 1067 · 4,876 characters · source document
Read the full text
PRINTER'S NO. 1067
THE GENERAL ASSEMBLY OF PENNSYLVANIA
HOUSE RESOLUTION
No. 137
Session of
2025
INTRODUCED BY MALAGARI, HILL-EVANS, FREEMAN, VENKAT, GIRAL,
KHAN, HADDOCK, SANCHEZ, CONKLIN, D. WILLIAMS, GREEN AND
CURRY, MARCH 19, 2025
REFERRED TO COMMITTEE ON HEALTH, MARCH 19, 2025
A RESOLUTION
1 Recognizing May 17, 2025, as "World Neurofibromatosis Awareness
2 Day" in Pennsylvania.
3 WHEREAS, The Children's Tumor Foundation annually observes
4 May 17 as "World Neurofibromatosis Awareness Day" to educate the
5 public about this rare genetic condition; and
6 WHEREAS, The global community recognizes the importance of
7 raising awareness about neurofibromatosis, its impact on
8 individuals and families and the need for continued research and
9 support; and
10 WHEREAS, Although more than 4 million people around the world
11 are living with neurofibromatosis and 1 in every 2,000 births is
12 diagnosed with neurofibromatosis, it is still relatively unknown
13 to the public; and
14 WHEREAS, Neurofibromatosis affects all populations equally,
15 regardless of race, ethnicity or gender; and
16 WHEREAS, Neurofibromatosis causes tumors to grow on nerves
17 throughout the body and also can affect development of the
1 brain, cardiovascular system, bones and skin; and
2 WHEREAS, The disorder can lead to blindness, deafness, bone
3 abnormalities, disfigurement, learning disabilities, disabling
4 pain and cancer; and
5 WHEREAS, There are three different types of
6 neurofibromatosis: neurofibromatosis type 1, neurofibromatosis
7 type 2 and schwannomatosis; and
8 WHEREAS, Signs of neurofibromatosis type 1 include light
9 brown spots on the skin, known as café au lait spots, bumps
10 known as Lisch nodules on the iris of the eye and freckles on
11 the groin or armpits; and
12 WHEREAS, Neurofibromatosis type 1 is one of the country's
13 most common genetic disorders occurring in approximately 1 in
14 2,500 births; and
15 WHEREAS, Neurofibromatosis type 2 is far less common,
16 occurring in 1 in 60,000 people, and is typically characterized
17 by tumors that grow on the nerves of the inner ear; and
18 WHEREAS, Schwannomatosis is a rarer form of neurofibromatosis
19 for which symptoms typically appear between ages 25 and 30; and
20 WHEREAS, Schwannomatosis often forms on the spinal or cranial
21 nerves and leads to symptoms like chronic pain or loss of
22 muscle; and
23 WHEREAS, Instances of neurofibromatosis occur due to
24 mutations that either occur during conception or are passed down
25 genetically through the parents; and
26 WHEREAS, Family history, physical exams and genetic tests are
27 currently used to diagnose neurofibromatosis in patients; and
28 WHEREAS, While there is currently no cure available, there
29 are multiple forms of treatment for patients dealing with
30 neurofibromatosis; and
20250HR0137PN1067 - 2 -
1 WHEREAS, Mild instances of neurofibromatosis often do not
2 require significant treatment outside of regular doctor visits
3 and observation; and
4 WHEREAS, More severe cases may require removal through
5 radiation or surgery done by a nerve tumor specialist or a team
6 of various surgeons; and
7 WHEREAS, There are currently no medications that have been
8 approved to treat neurofibromatosis, though researchers are
9 investigating various methods and therapies; and
10 WHEREAS, The Children's Tumor Foundation leads efforts to
11 promote and financially sponsor world-class medical research
12 aimed at finding effective treatments and, ultimately, a cure
13 for neurofibromatosis; and
14 WHEREAS, The Children's Tumor Foundation is connecting the
15 unconnected, leading the way through innovative and inventive
16 approaches to scientific advancement and improved patient care,
17 revamping systems to accelerate the path from discovery to
18 treatment; and
19 WHEREAS, The Children's Tumor Foundation provides patient and
20 family support through its information resources, youth programs
21 and community activities; and
22 WHEREAS, Much remains to be done in raising public awareness
23 of neurofibromatosis to help promote early diagnosis, proper
24 management and treatment, prevention of complications and
25 support for research; therefore be it
26 RESOLVED, That the House of Representatives recognize May 17,
27 2025, as "World Neurofibromatosis Awareness Day" in
28 Pennsylvania.
20250HR0137PN1067 - 3 -Connected on the graph
Outbound (1)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| — | referred_to_committee | Pennsylvania House Health Committee | — | pa-leg |
The full graph
Every typed relationship touching this entity — 1 edge across 1 category. Grouped by what the connection is; the heaviest few are shown, with a link to the full list.
Committees
→ Referred to committee 1 edge
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Steven R. Malagari (D, state_lower PA-53) | sponsor | 0 | — | 5 |
| 2 | Arvind Venkat (D, state_lower PA-30) | cosponsor | 0 | — | 1 |
| 3 | Benjamin V. Sanchez (D, state_lower PA-153) | cosponsor | 0 | — | 1 |
| 4 | Carol Hill-Evans (D, state_lower PA-95) | cosponsor | 0 | — | 1 |
| 5 | Dan K. Williams (D, state_lower PA-74) | cosponsor | 0 | — | 1 |
| 6 | G. Roni Green (D, state_lower PA-190) | cosponsor | 0 | — | 1 |
| 7 | Gina H. Curry (D, state_lower PA-164) | cosponsor | 0 | — | 1 |
| 8 | Jim Haddock (D, state_lower PA-118) | cosponsor | 0 | — | 1 |
| 9 | Jose Giral (D, state_lower PA-180) | cosponsor | 0 | — | 1 |
| 10 | Keith S. Harris (D, state_lower PA-195) | cosponsor | 0 | — | 1 |
| 11 | Robert Freeman (D, state_lower PA-136) | cosponsor | 0 | — | 1 |
| 12 | Scott Conklin (D, state_lower PA-77) | cosponsor | 0 | — | 1 |
| 13 | Tarik Khan (D, state_lower PA-194) | cosponsor | 0 | — | 1 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
0 predicted yes (0%) · 543 predicted no (100%) · 0 unknown (0%)
By party: · R: 0 yes / 277 no · D: 0 yes / 263 no · I: 0 yes / 3 no
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-20 · was referred to Pennsylvania House Health Committee · pa-leg